Synthesis, Cytotoxic Evaluation, and In Silico Studies of 4-Substituted Coumarins
Prabhjot Kaur
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001 India
Search for more papers by this authorRupinder Kaur Gill
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001 India
Research Scholar, Punjab Technical University, Kapurthala, Punjab, 144 601 India
Search for more papers by this authorGagandip Singh
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001 India
Search for more papers by this authorCorresponding Author
Jitender Bariwal
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001 India
Satiate Research and Anatech Pvt. Ltd., Panchkula, Haryana, 134102 India
E-mail: [email protected]Search for more papers by this authorPrabhjot Kaur
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001 India
Search for more papers by this authorRupinder Kaur Gill
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001 India
Research Scholar, Punjab Technical University, Kapurthala, Punjab, 144 601 India
Search for more papers by this authorGagandip Singh
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001 India
Search for more papers by this authorCorresponding Author
Jitender Bariwal
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001 India
Satiate Research and Anatech Pvt. Ltd., Panchkula, Haryana, 134102 India
E-mail: [email protected]Search for more papers by this authorAbstract
Two series of coumarins possessing the aniline- and heterocyclic ring at 4th position have been synthesized and evaluated for their in vitro cytotoxic activity against MCF-7 cancer cell line in MTT assay. Structure activity relationship (SAR) studies reveal that the electron donor group at position-8 of coumarin played an important role in cytotoxic activity. Compound VIId showed the potent cytotoxic activity followed by compound Xa with IC50 = 6.25 and 6.50 μM, respectively. A docking study has also been carried out for the most potent compound to get an insight into molecular interactions with p50 subunit of NF-κB protein.
References and Notes
- 1 What is Cancer? http://www.cancer.gov/cancertopics/understandingcancer/cancer/page1. Accessed 08 Sept 2014.
- 2Nelson, S. M.; Ferguson, L. R.; Denny, W. A. Cell Chromosome 2004, 3, 2.
- 3Hotta, K.; Ueoka, H. Crit Rev Oncol Hematol 2005, 55, 45.
- 4Mann, J. Nat Rev Cancer 2002, 2, 143.
- 5O'Kennedy, R.; Thornes, R. D. Coumarins: Biology, Applications and Mode of Action; John Wiley & Sons: Chichester, U.K., 1997.
- 6Hoult, J.; Paya, M. Gen Pharmacol-Vas Syst 1996, 27, 713.
- 7Riveiro, M. E.; Moglioni, A.; Vazquez, R.; Gomez, N.; Facorro, G.; Piehl, L.; de Celis, E. R.; Shayo, C.; Davio, C. Bioorg Med Chem 2008, 16, 2665.
- 8Feuer, G.; Kellen, J.; Kovacs, K. Oncology 1976, 33, 35.
- 9Kashman, Y.; Gustafson, K. R.; Fuller, R. W.; Cardellina, J. H.; McMahon, J. B.; Currens, M. J.; Buckheit Jr, R. W.; Hughes, S. H.; Cragg, G. M.; Boyd, M. R. [Erratum to document cited in CA117 (11): 108101g]. J Med Chem 1993, 36, 1110.
- 10Shikishima, Y.; Takaishi, Y.; Honda, G.; Ito, M.; Takeda, Y.; Kodzhimatov, O. K.; Ashurmetov, O.; Lee, K.-H. Chem Pharm Bull 2001, 49, 877.
- 11Gage, B. F. ASH Education Program Book, 2006, 467.
- 12Ostrov, D. A.; Prada, J. A. H.; Corsino, P. E.; Finton, K. A.; Le, N.; Rowe, T. C. Antimicrob Agents Chemother 2007, 51, 3688.
- 13Gormley, N. A.; Orphanides, G.; Meyer, A.; Cullis, P. M.; Maxwell, A. Biochem 1996, 35, 5083.
- 14Kontogiorgis, C. A.; Hadjipavlou-Litina, D. J. Bioorg Med Chem Lett 2004, 14, 611.
- 15Sashidhara, K. V.; Rosaiah, J. N.; Kumar, A.; Bhatia, G.; Khanna, A. Bioorg Med Chem Lett 2010, 20, 3065.
- 16Fylaktakidou, K. C.; Hadjipavlou-Litina, D. J.; Litinas, K. E.; Nicolaides, D. N. Curr Pharm Des 2004, 10, 3813.
- 17Omarbasha, B.; Fair, W. R.; Heston, W. D. Cancer Res 1989, 49, 3045.
- 18Marshall, M.; Kervin, K.; Benefield, C.; Umerani, A.; Albainy-Jenei, S.; Zhao, Q.; Khazaeli, M.. J Cancer Res Clin Oncol 1994, 120, S3.
- 19Kim, E.-K.; Kwon, K.-B.; Shin, B.-C.; Seo, E.-A.; Lee, Y.-R.; Kim, J.-S.; Park, J.-W.; Park, B.-H.; Ryu, D.-G. Life Sci 2005, 77, 824.
- 20Chu, C.-Y.; Tsai, Y.-Y.; Wang, C.-J.; Lin, W.-L.; Tseng, T.-H. Eur J Pharmacol 2001, 416, 25.
- 21Wang, X.; Bastow, K. F.; Sun, C.-M.; Lin, Y.-L.; Yu, H.-J.; Don, M.-J.; Wu, T.-S.; Nakamura, S.; Lee, K.-H. J Med Chem 2004, 47, 5816.
- 22Wang, X.; Nakagawa-Goto, K.; Bastow, K. F.; Don, M.-J.; Lin, Y.-L.; Wu, T.-S.; Lee, K.-H. J Med Chem 2006, 49, 5631.
- 23Dong, Y.; Shi, Q.; Pai, H.-C.; Peng, C.-Y.; Pan, S.-L.; Teng, C.-M.; Nakagawa-Goto, K.; Yu, D.; Liu, Y.-N.; Wu, P.-C. J Med Chem 2010, 53, 2299.
- 24Dholakia, V.; Parekh, M.; Trivedi, K. Aust J Chem 1968, 21, 2345.
- 25Saidu, N. E. B.; Valente, S.; Bana, E.; Kirsch, G.; Bagrel, D.; Montenarh, M. Bioorg Med Chem 2012, 20, 1584.
- 26Stefanachi, A.; Favia, A. D.; Nicolotti, O.; Leonetti, F.; Pisani, L.; Catto, M.; Zimmer, C.; Hartmann, R. W.; Carotti, A. J Med Chem 2011, 54, 1613.
- 27Kini, S. G.; Choudhary, S.; Mubeen, M. J Computat Methods Mol Des 2012, 2, 510.
- 28Tilala, D. D. V.; Pandeya, H.; Karia, D. J Chem Biol Phys Sci 2012, 2, 1724.
- 29Patel, D.; Kumari, P.; Patel, N.. J Chem Pharm Res 2010, 2, 84.
- 30Phoujdar, M. S.; Kathiravan, M. K.; Bariwal, J. B.; Shah, A. K.; Jain, K. S. Tetrahed Lett 2008, 49, 1269.
- 31Dua, P.; Gude, R. P. Cancer Chemoth Pharm 2006, 58, 195.
- 32 GOLD 5.0.1. Cambridge Crystallographic Data Centre: Cambridge U.K.
- 33Ghosh, G.; van Duyne, G.; Ghosh, S.; Sigler, P. B. Nature 1995, 373, 303.
- 34 MOE. 10: The Molecular Operating Environment from Chemical Computing Group Inc., 1255 University Street, Suite 1600, Montreal, Quebec, Canada H3B 3X3, 2010. http://www.chemcomp.com.
